3%-14% Glycosylated Hemoglobin Test Kit
Brand Name:ZOSBIO
Certification:CE
Model Number:HbA1c
Minimum Order Quantity:To be negotiated
Delivery Time:To be negotiated
Place of Origin:CHINA
Contact Now
Add to Cart
Active Member
Location:
Zhengzhou Henan China
Address:
Office Address: Building 4, No. 51 Jingbei 3rd Road, Jingkai Zone, Zhengzhou City. Henan Province,China.
Supplier`s last login times:
within 47 hours
Product Details
Company Profile
Product Details
Glycosylated Hemoglobin Test Reagent (HbA1c)
Overview of HbA1c
HbA1c overview glycosylated hemoglobin (HbA1c) is the product of the combination of hemoglobin in human red blood cells and sugars in serum. The combination of blood glucose and hemoglobin to produce glycosylated hemoglobin is an irreversible reaction. The occurrence of the reaction is proportional to the concentration of blood glucose, and can be maintained for about 120 days. Therefore, the detection of glycosylated hemoglobin can reflect the blood glucose control of patients in recent 8-12 weeks.
HbA1c performance index
| Detection range | sample size | Sample type | Test time |
| 3％~14％ | 10μl | Whole Blood | 15min |
Clinical significance of HbA1c
- Early screening and diagnosis of diabetes mellitus
- Effect evaluation of blood glucose control program
- Prediction of chronic complications of diabetes
- Differential diagnosis between stress hyperglycemia and diabetes mellitus
- Diagnosis and treatment monitoring of gestational diabetes mellitus (GDM)
| Glycated hemoglobin control objectives | Adapt to the crowd |
| <6% | ① There were no adverse reactions such as hypoglycemia and weight gain; ② No need for hypoglycemic drug intervention;③Diabetes mellitus complicated with pregnancy; ④Diabetes mellitus found during pregnancy |
| <6.5% | ① <65 years old, no diabetes complications and severe concomitant diseases. ②Plan for gestational diabetes mellitus |
| <7% | ① Patients under 65 years old were treated with insulin; ② Patients over 65 years old, without hypoglycemia risk, good organ function, and survival time > 15 years; ③Planned insulin treatment for gestational diabetes mellitus |
| ≤7.5% | Patients with cardiovascular disease or high risk of cardiovascular disease |
| <8% | The patients were over 65 years old and the expected survival time was 5-15 years |
| <9% | ① Patients over 65 years old or with malignant tumor have an expected survival time of less than 5 years; ② High risk group of hypoglycemia; ③ Those who are difficult to carry out the treatment plan, such as mental or intellectual or visual impairment, poor medical conditions, etc |
Application Department
Cardiology, laboratory, emergency, ICU, oncology, Nephrology,Pediatrics, endocrinology, gynecology, geriatrics, respiratory, thoracic surgery,Gastroenterology, Urology, etc
Clinical comparison of HbA1c
Company profile
Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise
engaged in the research and development, production and operation
of in vitro diagnostic products. The in vitro diagnostic products
developed by the company cover POCT series, microbial series,
biochemical series and immune series reagents and supporting
instruments.
The company has always adhered to the core concept of "fast and
accurate, living up to life", committed to providing society with
excellent products and services, and contributing to the cause of
human health.
3%-14% Glycosylated Hemoglobin Test Kit
Inquiry Cart
0